| Spanish Series of Patients Treated With the Radionuclide Lutetium177 (NCT04949282) | Sociedad Española de Medicina Nuclear e Imagen Molecular | 2021-05-10 |
| External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC (NCT04697446) | Blueprint Medicines Corporation | 2020-12-01 |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT04222972) | Hoffmann-La Roche | 2020-07-24 |
| Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients (NCT04657315) | CHA University | 2020-06-24 |
| HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors (NCT03911388) | M.D. Anderson Cancer Center | 2019-09-12 |
| Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases (NCT02859415) | National Cancer Institute (NCI) | 2019-08-08 |
| Avelumab in Refractory Testicular Germ Cell Cancer. (NCT03403777) | National Cancer Institute, Slovakia | 2017-11-15 |
| Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types (NCT03012620) | UNICANCER | 2017-07-05 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (NCT03037385) | Hoffmann-La Roche | 2017-03-17 |
| Multicenter Database of Patients With Germ Cell Tumor (NCT02863003) | Latin American Cooperative Oncology Group | 2016-09-01 |
| Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy (NCT02839694) | National Cancer Institute (NCI) | 2016-07-07 |
| Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse (NCT02679950) | Nasser Hanna | 2015-11-20 |
| Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor (NCT02533765) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2015-09-11 |
| Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients (NCT00393861) | Indiana University | 2006-10-01 |
| Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin (NCT00611962) | Sanofi | 2000-12-01 |
| Vorasidenib Expanded Access Program (NCT05592743) | Servier | |